This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Christensen, H. D. Articles by Coleman, F. H. Search for Related Content PubMed PubMed Citation Articles by Christensen, H. D. Articles by Sienko, A. E. Articles by Rayburn, W. F. Articles by Gonzalez, C. L. Articles by Coleman, F. H. Social Bookmarking                         What's this?

A Placebo-Controlled, Blinded Comparison Between Betamethasone and Dexamethasone to Enhance Lung Maturation in the Fetal Mouse

Anna E. Sienko, MD

William F. Rayburn, MD

Christina L. Gonzalez, BS

Frederick H. Coleman, MD

Maternal-Fetal Pharmacology Research Program, Section of Maternal-Fetal Medicine, Department of Obsterics and Gynecology, Department of Pharmacology and Toxicology, and Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Objective: To compare the effects of betamethasone and dexamethasone used to enhance lung maturity of the fetal mouse.

Methods: Adult CD-1 mice were administered a single does of either a placebo or different strengths of betamethasone (0.01, 0.025, or 0.10 mg) or dexamethasone (0.025 or 0.10 mg) on day 14.0 (74%) of gestation. The either gravid mice in each treatment cohort were killed on day 16.5 to assess fetal lung maturity (histologic changes and respiratory patterns) in a blinded manner. Another ten gravid mice in each treatment group were allowed to deliver spontaneously to assess perinatal outcomes.

Results: Compared with the effects from placebo exposure, the 0.10-mg doese of both betamethasone and dexamethasone demonstrated enhanced histologic maturational changes and improved neonatal respiratory efforts. Betamethasone was twofold to threefold more potent than dexamethasone. The fetal crown-rump lengths and the fetal body, lung, and heart weights were indistinguishable among the three treatment groups. Compared with the fetal liver weight in the placebo group 955.0 ± 2.2mg), the liver was less heavy after exposure to 0.10 mg of betamethasone (45.6 ± 2.0 mg; P <.005), 0.025 mg of dexamethasone (47.6 ± 1.7 mg; P <.02), or 0.10 mg of dexamethasone (43.8 ± 1.5 mg; P <.001). No significant differences were observed between the 0.01-mg treatments of either corticosteroid and placebo for the duration of gestation, litter size, survival rate, birth weights, or weight gains to postnatal day 26.

Conclusion: A single subcutaneous dose of 0.10 mg of betamethasone was twofold to threefold more potent than dexamethasone in accelerating fetal lung maturity without impairing fetal survival or weight gain. The unexpected finding of a reduced fetal liver weight with either corticosteroid warrants clinical correlation.

Key Words: Corticosteriods • fetus • lung maturation • perinatal outcomes • mouse

Journal of the Society for Gynecologic Investigation, Vol. 4, No. 3, 130-134 (1997)
DOI: 10.1177/107155769700400303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?